Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H18N4O3
CAS Number:
Molecular Weight:
266.30
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Quality Level
Assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
ethanol: 2 mg/mL
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
10-30°C
SMILES string
[nH]1c2c(nc1COC)N(C(=O)N(C2=O)C)CC(C)C
InChI
1S/C12H18N4O3/c1-7(2)5-16-10-9(11(17)15(3)12(16)18)13-8(14-10)6-19-4/h7H,5-6H2,1-4H3,(H,13,14)
InChI key
NBLBCGUCPBXKOV-UHFFFAOYSA-N
Related Categories
General description
A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC50 = 4 µM).
A cell-permeable, selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I, IC50 = 4 µM).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PDE 1
PDE 1
Product does not compete with ATP.
Reversible: no
Target IC50: 4 µM against Ca2+-calmodulin-dependent phosphodiesterase (PDE I)
Preparation Note
Following reconstitution aliquot and freeze at -20°C. Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Jackson, E.K., et al. 1997. J. Cardiovasc. Pharmacol. 30, 798.
Ahn, H.S., et al. 1989. Biochem. Pharmacol.38, 3331.
Han, P., et al. 1989. J. Biol. Chem.274, 22337.
Ahn, H.S., et al. 1989. Biochem. Pharmacol.38, 3331.
Han, P., et al. 1989. J. Biol. Chem.274, 22337.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
E K Jackson et al.
Journal of cardiovascular pharmacology, 30(6), 798-801 (1998-01-22)
The objective this investigation was to determine the relative importance of type I, III, and IV phosphodiesterases in the regulation of cyclic adenosine monophosphate (cAMP) in the renal circulation. In the first experimental series, four groups of isolated rat kidneys
H S Ahn et al.
Biochemical pharmacology, 38(19), 3331-3339 (1989-10-01)
In this study three forms of cyclic nucleotide phosphodiesterase (PDE) isolated from rabbit aorta were pharmacologically characterized, and the consequence of selective inhibition of calmodulin-stimulated PDE (CaM-PDE) and cGMP specific PDE (cG-PDE) was evaluated using PDE inhibitors. The cG-PDE (F1)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service